Milestone Pharmaceuticals (MIST) has released an update.
Milestone Pharmaceuticals has announced their progress with the drug etripamil, including plans to resubmit its New Drug Application for PSVT treatment in early Q2 2024 and a recent public offering that raised approximately $32.4 million to fund development. The FDA has provided guidance for a potential Phase 3 study for AFib-RVR, with a meeting anticipated in mid-2024 to finalize study protocols. The company’s financing efforts have now secured a cash runway extending into 2026.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
